Submission date
02/09/2011
Registration date
17/11/2011
Last edited
21/12/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Retrospectively registered
? Protocol not yet added
? SAP not yet added
? Results not yet added and study completed for more than 2 years
? Raw data not yet added
Study completed

Plain English Summary

Not provided at time of registration

Study website

Contact information

Type

Scientific

Contact name

Dr Barry Peters

ORCID ID

Contact details

Harrison Wing
2nd Floor Lambeth Wing
St. Thomas' Hospital
Westminster Bridge Road
London
SE1 7EH
United Kingdom

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Protocol/serial number

PB002

Study information

Scientific title

A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options - Vitamin D sub study

Acronym

Study hypothesis

To explore the effects and potential benefits of high doses of vitamin D supplementation on various parameters of the immune system

Ethics approval(s)

NRES Committee London - Westminster, approval pending

Study design

Phase IV open label study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type

Treatment

Patient information sheet

Not available in web format, please contact HW.Research@gstt.nhs.uk to request a patient information sheet

Condition

Human immunodeficiency virus (HIV)

Intervention

There are no treatment arms, there are 3 cohorts: HIV positive (on treatment), HIV Positive (Naive), HIV Negative. All are given 200,000 units stat colecalciferol at baseline and followed up over a 12 week period by doing physical exam, blood samples and urine samples.

Intervention type

Supplement

Primary outcome measure

1. Efficacy: level in serum vitamin D levels to be above those at baseline
2. Safety:
2.1. Routine: serum renal, liver, bone, glucose, Full Blood Count (FBC)
2.2. Vital signs including blood pressure (BP), pulse, temperature
2.3. Renal: urine dipstix (blood, protein, leukocytes, glucose), urine protein/creatinine (PCR)
2.4. Bone biochemisty to include: Vitamin D, parathyroid hormone, alkaline phosphatase (ALP)
Samples obtained at baseline, week 4 and week 12

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/11/2011

Overall study end date

01/03/2012

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Aged between 18 years and 45 years , males and females
2. Documented Positive HIV-1 antibody test and either stable on highly active antiretroviral therapy (HAART) as defined by undetectable viral load and on the same regimen for more than 6 months or treatment naive (HIV+ cohort only) (n=32)
3. Presumed HIV negative C (HIV negative cohort only) (n=16)
4. Ability to give informed consent
5. Willing to use barrier method contraception (condoms) for the duration of the trial
6. Documented Vitamin D deficiency (less than 50 nmol/L within 6 months of screening)
7. Not currently taking Vitamin D supplements, or have taken any Vitamin D supplements within 4 weeks of screening

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

48

Participant exclusion criteria

1. Pregnancy or breast feeding
2. Patient unlikely to comply with protocol
3. Received vitamin D supplementation within the previous 4 weeks
4. Documented history of renal impairment
5. Any chronic inflammatory condition
6. Documented Hepatitis B or C
7. Documented soya or peanut allergy or hypersensitivity to any of the constituents of Dekristol®
8. Hypercalcaemia or hypercalciuria
9. Pseudohypoparathyroidism

Recruitment start date

01/11/2011

Recruitment end date

01/03/2012

Locations

Countries of recruitment

England, United Kingdom

Study participating centre

St. Thomas' Hospital
London
SE1 7EH
United Kingdom

Sponsor information

Organisation

King's College London - Guy's and St Thomas' NHS Foundation Trust (UK)

Sponsor details

Joint Clinical Trials Office
16th Floor Tower Wing
Guy's Hospital
Great Maze Pond
London
SE1 9RT
England
United Kingdom

Sponsor type

Hospital/treatment centre

Website

http://www.kcl.ac.uk/nursing/partners/nhs/gstt.aspx

ROR

https://ror.org/00j161312

Funders

Funder type

Industry

Funder name

ViiV Pharmaceuticals (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Additional files

Editorial Notes

21/12/2017: No publications found, verifying study status with principal investigator.